Alan Y. Lu, Executive VP of Sirnaomics, discusses with Scrip’s Brian Yang how the US-China hybrid looks to develop RNAi therapies simultaneously in the two countries.
RNAi is relatively new in China, where most innovative companies are betting either on small molecular or monoclonal antibodies. Sirnaomics, with its headquarters in Gaithersburg, MD and subsidiaries in Suzhou and Guangzhou, has filed the first investigative new drug (IND) with China FDA for its STP705, studied for hypertrophic skin scars.
On May 1, Suzhou Siraonomics announced it obtained the approval to start the study, the first for such small interfering RNA (siRNA) therapy in China, where in the US a Phase IIa clinical study of STP705 for the same indication is ongoing.
Its pipeline includes anti-fibrosis and anti-cancer compounds developed using proprietary algorithm for siRNA sequencing.
Last May, the company completed a Series B financing of USD 10 million led by Hong Kong-based Value Measured Investment Limited.
This interview was recorded at ChinaBio® Partnering Forum organized by EBD Group and ChinaBio® Group in Zhuhai, Guangdong, in May 2017.